{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Directory changed to C:\\Users\\pablosal\\Desktop\\gbb-ai-hls-factory-prior-auth\n"
     ]
    }
   ],
   "source": [
    "import os\n",
    "import pprint\n",
    "\n",
    "# Define the target directory\n",
    "target_directory = r\"C:\\Users\\pablosal\\Desktop\\gbb-ai-hls-factory-prior-auth\"  # change your directory here\n",
    "\n",
    "# Check if the directory exists\n",
    "if os.path.exists(target_directory):\n",
    "    # Change the current working directory\n",
    "    os.chdir(target_directory)\n",
    "    print(f\"Directory changed to {os.getcwd()}\")\n",
    "else:\n",
    "    print(f\"Directory {target_directory} does not exist.\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Understanding Semantic Kernel Components\n",
    "\n",
    "Before diving into the implementation, let's understand the key components of Semantic Kernel.\n",
    "\n",
    "#### The Kernel\n",
    "\n",
    "The Kernel is the central orchestrator in Semantic Kernel. It manages:\n",
    "\n",
    "- **Connecting to AI Models**: Interfaces with various AI models via connectors.\n",
    "- **Registering and Invoking Plugins**: Manages the lifecycle and execution of plugins.\n",
    "- **Managing Memory and Context**: Maintains state and context across interactions.\n",
    "- **Interacting with the Planner**: Coordinates with the Planner to achieve specified goals.\n",
    "\n",
    "#### Connectors\n",
    "\n",
    "Connectors allow the Kernel to interface with various AI models and services. They define how the Kernel communicates with these models, whether they're:\n",
    "\n",
    "- **OpenAI Models**: Such as GPT-3.5, GPT-4.\n",
    "- **Azure OpenAI Services**: Leveraging Microsoft's cloud-based AI capabilities.\n",
    "- **Local Models**: Using libraries like Hugging Face Transformers.\n",
    "\n",
    "#### Plugins\n",
    "\n",
    "Plugins are modular units that extend the Kernel's functionality. They consist of:\n",
    "\n",
    "- **Prompt Functions**: Use natural language prompts to interact with AI models.\n",
    "- **Native Functions**: Written in Python, performing deterministic tasks or interfacing with external services.\n",
    "\n",
    "Plugins act as building blocks for complex workflows.\n",
    "\n",
    "#### The Planner\n",
    "\n",
    "The Planner uses AI to dynamically create a sequence of actions (a plan) to achieve a specified goal. It considers:\n",
    "\n",
    "- **Available Plugins and Their Functions**: Understands the capabilities of each plugin.\n",
    "- **Function Descriptions**: Uses metadata to understand what each function does.\n",
    "- **Combining Functions**: Determines how functions can be combined to fulfill the goal.\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### ðŸŒŸ Creating a Multi-Agent Architecture for Medical Research Documentation\n",
    "\n",
    "In the realm of medical research, producing high-quality documentation is crucial. This guide aims to design a multi-agent system consisting of three specialized agents:\n",
    "\n",
    "- **Medical Researcher**: Gathers and summarizes relevant medical information.\n",
    "- **Clinical Evaluator**: Assesses the clinical relevance and accuracy of the information.\n",
    "- **Medical Editor**: Refines the language and ensures adherence to medical writing standards.\n",
    "\n",
    "Using Semantic Kernel's capabilities, we'll create plugins representing these agents and use a Planner to dynamically orchestrate their workflow based on a given goal.\n",
    "\n",
    "By leveraging Semantic Kernel's capabilities, we can create a robust single-agent and sophisticated multi-agent system. Let's do it !\n",
    "\n",
    "### Implementation\n",
    "\n",
    "We will:\n",
    "\n",
    "1. **Define Plugins**: Create plugins for the Medical Researcher, Clinical Evaluator, and Medical Editor.\n",
    "2. **Configure the Kernel**: Set up the Kernel with the necessary connectors and plugins.\n",
    "3. **Develop the Planner**: Implement the Planner to dynamically orchestrate the workflow.\n",
    "4. **Execute the Plan**: Run the system to produce high-quality medical documentation."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "We are using the following semantic_kernel library version: 1.17.0\n"
     ]
    }
   ],
   "source": [
    "#!pip install semantic-kernel --upgrade\n",
    "import semantic_kernel as sk\n",
    "print(f\"We are using the following semantic_kernel library version: {sk.__version__}\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## 1. Define Plugins\n",
    "\n",
    "We have defined the plugin for MedicalAgents located in the specified directory  `C:\\Users\\pablosal\\Desktop\\gbbai-agent-architecture-lab\\src\\plugins\\plugins_store`"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## 2. Configure The Kernel"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "import semantic_kernel as sk\n",
    "\n",
    "# Initialize the kernel\n",
    "kernel = sk.Kernel()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "# add Azure OpenAI service connector to the kernel\n",
    "import os\n",
    "from semantic_kernel import Kernel\n",
    "from semantic_kernel.connectors.ai.open_ai import AzureChatCompletion\n",
    "\n",
    "# Load environment variables from a .env file\n",
    "from dotenv import load_dotenv\n",
    "load_dotenv()\n",
    "\n",
    "AZURE_OPENAI_KEY = os.getenv(\"AZURE_OPENAI_KEY\")\n",
    "AZURE_OPENAI_ENDPOINT = os.getenv(\"AZURE_OPENAI_API_ENDPOINT\")\n",
    "AZURE_OPENAI_API_VERSION = os.getenv(\"AZURE_OPENAI_API_VERSION\")\n",
    "AZURE_OPENAI_EMBEDDING_DEPLOYMENT = os.getenv(\"AZURE_OPENAI_EMBEDDING_DEPLOYMENT\")\n",
    "AZURE_OPENAI_CHAT_DEPLOYMENT_ID = os.getenv(\"AZURE_OPENAI_CHAT_DEPLOYMENT_ID\")\n",
    "\n",
    "service_id = \"gpt-4o\"\n",
    "# Add Azure OpenAI chat completion\n",
    "kernel.add_service(AzureChatCompletion(\n",
    "    service_id=service_id,\n",
    "    deployment_name=AZURE_OPENAI_CHAT_DEPLOYMENT_ID,\n",
    "    api_key=AZURE_OPENAI_KEY,\n",
    "    endpoint=AZURE_OPENAI_ENDPOINT,\n",
    "    api_version=AZURE_OPENAI_API_VERSION,\n",
    "))\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "2024-12-18 19:40:26,113 - AIPolicyEvaluationPlugin - MainProcess - INFO     OpenAI client initialized successfully. (aievaluator.py:__init__:92)\n",
      "[2024-12-18 19:40:26 - AIPolicyEvaluationPlugin:92 - INFO] OpenAI client initialized successfully.\n",
      "2024-12-18 19:40:26,119 - AgenticRAG - Plugin AzureSearchPlugin - MainProcess - INFO     Initializing SearchClient with endpoint: https://search-ai-factory-centralus.search.windows.net, index_name: ai-policies-index (aisearch.py:__init__:49)\n",
      "[2024-12-18 19:40:26 - AgenticRAG - Plugin AzureSearchPlugin:49 - INFO] Initializing SearchClient with endpoint: https://search-ai-factory-centralus.search.windows.net, index_name: ai-policies-index\n",
      "2024-12-18 19:40:26,119 - AgenticRAG - Plugin AzureSearchPlugin - MainProcess - INFO     SearchClient initialized successfully. (aisearch.py:__init__:52)\n",
      "[2024-12-18 19:40:26 - AgenticRAG - Plugin AzureSearchPlugin:52 - INFO] SearchClient initialized successfully.\n",
      "2024-12-18 19:40:26,504 - AIQueryClassificationPlugin - MainProcess - INFO     OpenAI client initialized successfully. (aisearchclassification.py:__init__:91)\n",
      "[2024-12-18 19:40:26 - AIQueryClassificationPlugin:91 - INFO] OpenAI client initialized successfully.\n",
      "[2024-12-18 19:40:26 - semantic_kernel.functions.kernel_plugin:350 - WARNING] Failed to create function from Python file: C:\\Users\\pablosal\\Desktop\\gbb-ai-hls-factory-prior-auth\\src\\agenticai\\plugins\\plugins_store\\retrieval\\__init__.py\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "{'retrieval': KernelPlugin(name='retrieval', description=None, functions={'evaluate_search_results': KernelFunctionFromMethod(metadata=KernelFunctionMetadata(name='evaluate_search_results', plugin_name='retrieval', description='Evaluates search results against a query to extract the most relevant policy paths.', parameters=[KernelParameterMetadata(name='query_text', description=\"The user's search query.\", default_value=None, type_='str', is_required=True, type_object=<class 'str'>, schema_data={'type': 'string', 'description': \"The user's search query.\"}, include_in_function_choices=True), KernelParameterMetadata(name='search_results', description='The list of search results to evaluate.', default_value=None, type_='list[dict[str, str]]', is_required=True, type_object=typing.List[typing.Dict[str, str]], schema_data={'type': 'array', 'items': {'type': 'object', 'additionalProperties': {'type': 'string'}}, 'description': 'The list of search results to evaluate.'}, include_in_function_choices=True)], is_prompt=False, is_asynchronous=True, return_parameter=KernelParameterMetadata(name='return', description='The evaluated result, containing policy paths, reasoning, and retry flag.', default_value=None, type_='str', is_required=True, type_object=<class 'str'>, schema_data={'type': 'string', 'description': 'The evaluated result, containing policy paths, reasoning, and retry flag.'}, include_in_function_choices=True), additional_properties={}), invocation_duration_histogram=<opentelemetry.metrics._internal.instrument._ProxyHistogram object at 0x000002683F9C5540>, streaming_duration_histogram=<opentelemetry.metrics._internal.instrument._ProxyHistogram object at 0x000002683F9C5390>, method=<bound method AIPolicyEvaluationPlugin.evaluate_search_results of <aievaluator.AIPolicyEvaluationPlugin object at 0x00000268094195A0>>, stream_method=None), 'hybrid_search': KernelFunctionFromMethod(metadata=KernelFunctionMetadata(name='hybrid_search', plugin_name='retrieval', description='Performs a hybrid search using both keyword and vector search techniques.', parameters=[KernelParameterMetadata(name='search_text', description=None, default_value=None, type_='str', is_required=True, type_object=<class 'str'>, schema_data={'type': 'string'}, include_in_function_choices=True), KernelParameterMetadata(name='top', description=None, default_value=5, type_='int', is_required=False, type_object=<class 'int'>, schema_data={'type': 'integer'}, include_in_function_choices=True)], is_prompt=False, is_asynchronous=False, return_parameter=KernelParameterMetadata(name='return', description='A list of search results for the hybrid query', default_value=None, type_='list[dict[str, typing.Any]]', is_required=True, type_object=<class 'list'>, schema_data={'type': 'array', 'description': 'A list of search results for the hybrid query'}, include_in_function_choices=True), additional_properties={}), invocation_duration_histogram=<opentelemetry.metrics._internal.instrument._ProxyHistogram object at 0x000002683F9C5750>, streaming_duration_histogram=<opentelemetry.metrics._internal.instrument._ProxyHistogram object at 0x000002683F9C5600>, method=<bound method AzureSearchPlugin.hybrid_search of <aisearch.AzureSearchPlugin object at 0x000002683F9C5510>>, stream_method=None), 'keyword_search': KernelFunctionFromMethod(metadata=KernelFunctionMetadata(name='keyword_search', plugin_name='retrieval', description='Performs a keyword-based search against the Azure AI Search index.', parameters=[KernelParameterMetadata(name='search_text', description=None, default_value=None, type_='str', is_required=True, type_object=<class 'str'>, schema_data={'type': 'string'}, include_in_function_choices=True), KernelParameterMetadata(name='top', description=None, default_value=5, type_='int', is_required=False, type_object=<class 'int'>, schema_data={'type': 'integer'}, include_in_function_choices=True)], is_prompt=False, is_asynchronous=False, return_parameter=KernelParameterMetadata(name='return', description='A list of search results for the keyword query', default_value=None, type_='list[dict[str, typing.Any]]', is_required=True, type_object=<class 'list'>, schema_data={'type': 'array', 'description': 'A list of search results for the keyword query'}, include_in_function_choices=True), additional_properties={}), invocation_duration_histogram=<opentelemetry.metrics._internal.instrument._ProxyHistogram object at 0x000002683F9C6110>, streaming_duration_histogram=<opentelemetry.metrics._internal.instrument._ProxyHistogram object at 0x000002683F9C6140>, method=<bound method AzureSearchPlugin.keyword_search of <aisearch.AzureSearchPlugin object at 0x000002683F9C5510>>, stream_method=None), 'semantic_search': KernelFunctionFromMethod(metadata=KernelFunctionMetadata(name='semantic_search', plugin_name='retrieval', description='Performs a semantic search using Azure AI Search.', parameters=[KernelParameterMetadata(name='search_text', description=None, default_value=None, type_='str', is_required=True, type_object=<class 'str'>, schema_data={'type': 'string'}, include_in_function_choices=True), KernelParameterMetadata(name='top', description=None, default_value=5, type_='int', is_required=False, type_object=<class 'int'>, schema_data={'type': 'integer'}, include_in_function_choices=True)], is_prompt=False, is_asynchronous=False, return_parameter=KernelParameterMetadata(name='return', description='A list of search results for the semantic query', default_value=None, type_='list[dict[str, typing.Any]]', is_required=True, type_object=<class 'list'>, schema_data={'type': 'array', 'description': 'A list of search results for the semantic query'}, include_in_function_choices=True), additional_properties={}), invocation_duration_histogram=<opentelemetry.metrics._internal.instrument._ProxyHistogram object at 0x000002683F9C61A0>, streaming_duration_histogram=<opentelemetry.metrics._internal.instrument._ProxyHistogram object at 0x000002683F9C6200>, method=<bound method AzureSearchPlugin.semantic_search of <aisearch.AzureSearchPlugin object at 0x000002683F9C5510>>, stream_method=None), 'classify_search_query': KernelFunctionFromMethod(metadata=KernelFunctionMetadata(name='classify_search_query', plugin_name='retrieval', description=\"Classifies a query into 'keyword', 'semantic', or 'hybrid' using LLM reasoning.\", parameters=[KernelParameterMetadata(name='query_text', description=\"The user's search query to be classified.\", default_value=None, type_='str', is_required=True, type_object=<class 'str'>, schema_data={'type': 'string', 'description': \"The user's search query to be classified.\"}, include_in_function_choices=True)], is_prompt=False, is_asynchronous=True, return_parameter=KernelParameterMetadata(name='return', description=\"The classification for the query as 'keyword', 'semantic', or 'hybrid'.\", default_value=None, type_='str', is_required=True, type_object=<class 'str'>, schema_data={'type': 'string', 'description': \"The classification for the query as 'keyword', 'semantic', or 'hybrid'.\"}, include_in_function_choices=True), additional_properties={}), invocation_duration_histogram=<opentelemetry.metrics._internal.instrument._ProxyHistogram object at 0x000002683F9C7D90>, streaming_duration_histogram=<opentelemetry.metrics._internal.instrument._ProxyHistogram object at 0x000002683F9C7BE0>, method=<bound method AIQueryClassificationPlugin.classify_query of <aisearchclassification.AIQueryClassificationPlugin object at 0x000002683F9C56F0>>, stream_method=None)})}"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import os\n",
    "\n",
    "# Define the parent directory and plugin name\n",
    "parent_directory = os.path.abspath(os.path.join(\"src\", \"agenticai\", \"plugins\", \"plugins_store\"))\n",
    "plugin_name = \"retrieval\"\n",
    "\n",
    "# Add the plugin to the kernel\n",
    "plugin = kernel.add_plugin(parent_directory=parent_directory, plugin_name=plugin_name)\n",
    "\n",
    "kernel.plugins"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'evaluate_search_results': KernelFunctionFromMethod(metadata=KernelFunctionMetadata(name='evaluate_search_results', plugin_name='retrieval', description='Evaluates search results against a query to extract the most relevant policy paths.', parameters=[KernelParameterMetadata(name='query_text', description=\"The user's search query.\", default_value=None, type_='str', is_required=True, type_object=<class 'str'>, schema_data={'type': 'string', 'description': \"The user's search query.\"}, include_in_function_choices=True), KernelParameterMetadata(name='search_results', description='The list of search results to evaluate.', default_value=None, type_='list[dict[str, str]]', is_required=True, type_object=typing.List[typing.Dict[str, str]], schema_data={'type': 'array', 'items': {'type': 'object', 'additionalProperties': {'type': 'string'}}, 'description': 'The list of search results to evaluate.'}, include_in_function_choices=True)], is_prompt=False, is_asynchronous=True, return_parameter=KernelParameterMetadata(name='return', description='The evaluated result, containing policy paths, reasoning, and retry flag.', default_value=None, type_='str', is_required=True, type_object=<class 'str'>, schema_data={'type': 'string', 'description': 'The evaluated result, containing policy paths, reasoning, and retry flag.'}, include_in_function_choices=True), additional_properties={}), invocation_duration_histogram=<opentelemetry.metrics._internal.instrument._ProxyHistogram object at 0x000002683F9C5540>, streaming_duration_histogram=<opentelemetry.metrics._internal.instrument._ProxyHistogram object at 0x000002683F9C5390>, method=<bound method AIPolicyEvaluationPlugin.evaluate_search_results of <aievaluator.AIPolicyEvaluationPlugin object at 0x00000268094195A0>>, stream_method=None),\n",
       " 'hybrid_search': KernelFunctionFromMethod(metadata=KernelFunctionMetadata(name='hybrid_search', plugin_name='retrieval', description='Performs a hybrid search using both keyword and vector search techniques.', parameters=[KernelParameterMetadata(name='search_text', description=None, default_value=None, type_='str', is_required=True, type_object=<class 'str'>, schema_data={'type': 'string'}, include_in_function_choices=True), KernelParameterMetadata(name='top', description=None, default_value=5, type_='int', is_required=False, type_object=<class 'int'>, schema_data={'type': 'integer'}, include_in_function_choices=True)], is_prompt=False, is_asynchronous=False, return_parameter=KernelParameterMetadata(name='return', description='A list of search results for the hybrid query', default_value=None, type_='list[dict[str, typing.Any]]', is_required=True, type_object=<class 'list'>, schema_data={'type': 'array', 'description': 'A list of search results for the hybrid query'}, include_in_function_choices=True), additional_properties={}), invocation_duration_histogram=<opentelemetry.metrics._internal.instrument._ProxyHistogram object at 0x000002683F9C5750>, streaming_duration_histogram=<opentelemetry.metrics._internal.instrument._ProxyHistogram object at 0x000002683F9C5600>, method=<bound method AzureSearchPlugin.hybrid_search of <aisearch.AzureSearchPlugin object at 0x000002683F9C5510>>, stream_method=None),\n",
       " 'keyword_search': KernelFunctionFromMethod(metadata=KernelFunctionMetadata(name='keyword_search', plugin_name='retrieval', description='Performs a keyword-based search against the Azure AI Search index.', parameters=[KernelParameterMetadata(name='search_text', description=None, default_value=None, type_='str', is_required=True, type_object=<class 'str'>, schema_data={'type': 'string'}, include_in_function_choices=True), KernelParameterMetadata(name='top', description=None, default_value=5, type_='int', is_required=False, type_object=<class 'int'>, schema_data={'type': 'integer'}, include_in_function_choices=True)], is_prompt=False, is_asynchronous=False, return_parameter=KernelParameterMetadata(name='return', description='A list of search results for the keyword query', default_value=None, type_='list[dict[str, typing.Any]]', is_required=True, type_object=<class 'list'>, schema_data={'type': 'array', 'description': 'A list of search results for the keyword query'}, include_in_function_choices=True), additional_properties={}), invocation_duration_histogram=<opentelemetry.metrics._internal.instrument._ProxyHistogram object at 0x000002683F9C6110>, streaming_duration_histogram=<opentelemetry.metrics._internal.instrument._ProxyHistogram object at 0x000002683F9C6140>, method=<bound method AzureSearchPlugin.keyword_search of <aisearch.AzureSearchPlugin object at 0x000002683F9C5510>>, stream_method=None),\n",
       " 'semantic_search': KernelFunctionFromMethod(metadata=KernelFunctionMetadata(name='semantic_search', plugin_name='retrieval', description='Performs a semantic search using Azure AI Search.', parameters=[KernelParameterMetadata(name='search_text', description=None, default_value=None, type_='str', is_required=True, type_object=<class 'str'>, schema_data={'type': 'string'}, include_in_function_choices=True), KernelParameterMetadata(name='top', description=None, default_value=5, type_='int', is_required=False, type_object=<class 'int'>, schema_data={'type': 'integer'}, include_in_function_choices=True)], is_prompt=False, is_asynchronous=False, return_parameter=KernelParameterMetadata(name='return', description='A list of search results for the semantic query', default_value=None, type_='list[dict[str, typing.Any]]', is_required=True, type_object=<class 'list'>, schema_data={'type': 'array', 'description': 'A list of search results for the semantic query'}, include_in_function_choices=True), additional_properties={}), invocation_duration_histogram=<opentelemetry.metrics._internal.instrument._ProxyHistogram object at 0x000002683F9C61A0>, streaming_duration_histogram=<opentelemetry.metrics._internal.instrument._ProxyHistogram object at 0x000002683F9C6200>, method=<bound method AzureSearchPlugin.semantic_search of <aisearch.AzureSearchPlugin object at 0x000002683F9C5510>>, stream_method=None),\n",
       " 'classify_search_query': KernelFunctionFromMethod(metadata=KernelFunctionMetadata(name='classify_search_query', plugin_name='retrieval', description=\"Classifies a query into 'keyword', 'semantic', or 'hybrid' using LLM reasoning.\", parameters=[KernelParameterMetadata(name='query_text', description=\"The user's search query to be classified.\", default_value=None, type_='str', is_required=True, type_object=<class 'str'>, schema_data={'type': 'string', 'description': \"The user's search query to be classified.\"}, include_in_function_choices=True)], is_prompt=False, is_asynchronous=True, return_parameter=KernelParameterMetadata(name='return', description=\"The classification for the query as 'keyword', 'semantic', or 'hybrid'.\", default_value=None, type_='str', is_required=True, type_object=<class 'str'>, schema_data={'type': 'string', 'description': \"The classification for the query as 'keyword', 'semantic', or 'hybrid'.\"}, include_in_function_choices=True), additional_properties={}), invocation_duration_histogram=<opentelemetry.metrics._internal.instrument._ProxyHistogram object at 0x000002683F9C7D90>, streaming_duration_histogram=<opentelemetry.metrics._internal.instrument._ProxyHistogram object at 0x000002683F9C7BE0>, method=<bound method AIQueryClassificationPlugin.classify_query of <aisearchclassification.AIQueryClassificationPlugin object at 0x000002683F9C56F0>>, stream_method=None)}"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "plugin.functions"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## 3. Develop the Planer"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [],
   "source": [
    "from semantic_kernel.connectors.ai.chat_completion_client_base import ChatCompletionClientBase\n",
    "from semantic_kernel.connectors.ai.open_ai.prompt_execution_settings.azure_chat_prompt_execution_settings import (\n",
    "    AzureChatPromptExecutionSettings,\n",
    ")\n",
    "from semantic_kernel.connectors.ai.function_choice_behavior import FunctionChoiceBehavior\n",
    "\n",
    "chat_completion : AzureChatCompletion = kernel.get_service(type=ChatCompletionClientBase)\n",
    "execution_settings = AzureChatPromptExecutionSettings()\n",
    "execution_settings.function_choice_behavior = FunctionChoiceBehavior.Auto() # the automatic planning loop https://learn.microsoft.com/en-us/semantic-kernel/concepts/planning?pivots=programming-language-python#the-automatic-planning-loop"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## 4. Execute the Plan"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "2024-12-18 18:22:23,012 - AIQueryClassificationPlugin - MainProcess - INFO     Classifying query: The impact of AI on medical diagnostics (aisearchclassification.py:classify_query:109)\n",
      "[2024-12-18 18:22:23 - AIQueryClassificationPlugin:109 - INFO] Classifying query: The impact of AI on medical diagnostics\n",
      "2024-12-18 18:22:23,014 - micro - MainProcess - INFO     Function generate_chat_response started at 2024-12-18 18:22:23 (aoai_helper.py:generate_chat_response:370)\n",
      "[2024-12-18 18:22:23 - micro:370 - INFO] Function generate_chat_response started at 2024-12-18 18:22:23\n",
      "2024-12-18 18:22:23,017 - micro - MainProcess - INFO     Sending request to Azure OpenAI at 2024-12-18 18:22:23 (aoai_helper.py:generate_chat_response:427)\n",
      "[2024-12-18 18:22:23 - micro:427 - INFO] Sending request to Azure OpenAI at 2024-12-18 18:22:23\n",
      "2024-12-18 18:22:23,358 - micro - MainProcess - INFO     Function generate_chat_response finished at 2024-12-18 18:22:23 (Duration: 0.34 seconds) (aoai_helper.py:generate_chat_response:481)\n",
      "[2024-12-18 18:22:23 - micro:481 - INFO] Function generate_chat_response finished at 2024-12-18 18:22:23 (Duration: 0.34 seconds)\n",
      "2024-12-18 18:22:23,360 - AIQueryClassificationPlugin - MainProcess - INFO     Query classified as: semantic (aisearchclassification.py:classify_query:127)\n",
      "[2024-12-18 18:22:23 - AIQueryClassificationPlugin:127 - INFO] Query classified as: semantic\n",
      "2024-12-18 18:22:23,935 - AgenticRAG - Plugin AzureSearchPlugin - MainProcess - INFO     Function semantic_search called. (aisearch.py:semantic_search:158)\n",
      "[2024-12-18 18:22:23 - AgenticRAG - Plugin AzureSearchPlugin:158 - INFO] Function semantic_search called.\n",
      "2024-12-18 18:22:24,309 - AgenticRAG - Plugin AzureSearchPlugin - MainProcess - INFO     Extracted results: ========================================\n",
      "ðŸ†” ID: 677854350e06_aHR0cHM6Ly9zdG9yYWdlYWVhc3R1c2ZhY3RvcnkuYmxvYi5jb3JlLndpbmRvd3MubmV0L3ByZS1hdXRoLXBvbGljaWVzL3BvbGljaWVzX29jci8wMDEucGRm0_normalized_images_7_pages_1\n",
      "ðŸ“‚ Source Doc Path: https://storageaeastusfactory.blob.core.windows.net/pre-auth-policies/policies_ocr/001.pdf\n",
      "ðŸ“œ Content: Grace Index, Leeds Enthesitis Score (LEI), Spondyloarthritis Consortium of Canada (SPARCC) enthesitis score, Leeds Dactylitis Instrument Score, Minimal Disease Activity (MDA), Psoriatic Arthritis Impact of Disease (PsAID- 12), and/or serum markers (e.g ., C-reactive protein, erythrocyte sedimentation rate). b) Compared with baseline (prior to initiating an adalimumab product), patient experienced an improvement in at least one symptom, such as less joint pain, morning stiffness, or fatigue; improved function or activities of daily living; or decreased soft tissue swelling in joints or tendon sheaths. 3 Pages - Cigna National Formulary Coverage - Policy:Inflammatory Conditions - Adalimumab Products Prior Authorization Policy\n",
      "ðŸ’¡ Caption: Grace Index, Leeds Enthesitis Score (LEI), Spondyloarthritis Consortium of Canada (SPARCC) enthesitis score, Leeds Dactylitis Instrument Score, Minimal Disease Activity (MDA),<em> Psoriatic Arthritis Impact of Disease </em>(PsAID- 12), and/or serum markers (e.g ., C-reactive protein, erythrocyte sedimentation rate). b) Compared with baseline (prior to.\n",
      "========================================\n",
      "\n",
      "========================================\n",
      "ðŸ†” ID: 677854350e06_aHR0cHM6Ly9zdG9yYWdlYWVhc3R1c2ZhY3RvcnkuYmxvYi5jb3JlLndpbmRvd3MubmV0L3ByZS1hdXRoLXBvbGljaWVzL3BvbGljaWVzX29jci8wMDUucGRm0_normalized_images_5_pages_0\n",
      "ðŸ“‚ Source Doc Path: https://storageaeastusfactory.blob.core.windows.net/pre-auth-policies/policies_ocr/005.pdf\n",
      "ðŸ“œ Content: UnitedHealthcareÂ® (a) Exemestane if progressed within 12 months or on a non-steroidal aromatase inhibitor [e.g ., Arimidex (anastrozole), Femara (letrozole)] (b) Fulvestrant (c) Tamoxifen Authorization will be issued for 12 months. 2. Reauthorization a. Afinitor will be approved based on the following criterion: (1) Patient does not show evidence of progressive disease while on Afinitor therapy Authorization will be issued for 12 months. H. Hodgkin Lymphoma 1. Initial Authorization a. Afinitor will be approved based on both of the following criteria: (1) Diagnosis of classic Hodgkin lymphoma -AND- (2) Disease is refractory to at least 3 prior lines of therapy Authorization will be issued for 12 months. 2. Reauthorization a. Afinitor will be approved based on the following criterion: (1) Patient does not show evidence of progressive disease while on Afinitor therapy Authorization will be issued for 12 months. I. Soft Tissue Sarcoma 1. Initial Authorization a. Afinitor will be approved b...\n",
      "ðŸ’¡ Caption: UnitedHealthcareÂ® (a)<em> Exemestane </em>if progressed within 12 months or on a<em> non-steroidal aromatase inhibitor </em>[e.g ., Arimidex (anastrozole), Femara (letrozole)] (b) Fulvestrant (c) Tamoxifen Authorization will be issued for 12 months.  ...<em> Afinitor therapy AuthorizationH</em>.<em> Hodgkin Lymphoma </em>1. <em>Afinitor </em>will be<em> approved </em>based on both of the following.\n",
      "========================================\n",
      "\n",
      "========================================\n",
      "ðŸ†” ID: 677854350e06_aHR0cHM6Ly9zdG9yYWdlYWVhc3R1c2ZhY3RvcnkuYmxvYi5jb3JlLndpbmRvd3MubmV0L3ByZS1hdXRoLXBvbGljaWVzL3BvbGljaWVzX29jci8wMDUucGRm0_normalized_images_4_pages_0\n",
      "ðŸ“‚ Source Doc Path: https://storageaeastusfactory.blob.core.windows.net/pre-auth-policies/policies_ocr/005.pdf\n",
      "ðŸ“œ Content: UnitedHealthcareÂ® (1) Patient does not show evidence of progressive disease while on Afinitor therapy Authorization will be issued for 12 months. G. Breast Cancer 1. Initial Authorization a. Afinitor will be approved based on all of the following criteria: (1) Diagnosis of breast cancer -AND- (2) One of the following: (a) Disease is recurrent (b) Disease is metastatic -AND- (3) Disease is hormone receptor (HR)-positive [i.e ., estrogen-receptor-positive (ER+) or progesterone-receptor-positive (PR+)] -AND- (4) Disease is human epidermal growth factor receptor 2 (HER2)-negative -AND- (5) One of the following: (a) Patient is a postmenopausal woman -OR- (b) Both of the following: i. Patient is a premenopausal woman ii. Patient is being treated with ovarian ablation/suppression -OR- (c) Patient is male -AND- (6) Used in combination with one of the following: C 2024 UnitedHealthcare Services, Inc. 5\n",
      "ðŸ’¡ Caption: UnitedHealthcareÂ® (1)<em> Patient does not show evidence of progressive disease </em>while on<em> Afinitor therapy Authorization </em>will be issued for 12 months. <em>Afinitor will be approved based on </em>all of the following criteria: (1)<em> Diagnosis of breast cancer </em>-AND- (2) One of the following: (a) Disease is recurrent (b) Disease is metasta... Patient is being.\n",
      "========================================\n",
      "\n",
      "========================================\n",
      "ðŸ†” ID: 677854350e06_aHR0cHM6Ly9zdG9yYWdlYWVhc3R1c2ZhY3RvcnkuYmxvYi5jb3JlLndpbmRvd3MubmV0L3ByZS1hdXRoLXBvbGljaWVzL3BvbGljaWVzX29jci8wMDUucGRm0_normalized_images_11_pages_0\n",
      "ðŸ“‚ Source Doc Path: https://storageaeastusfactory.blob.core.windows.net/pre-auth-policies/policies_ocr/005.pdf\n",
      "ðŸ“œ Content: UnitedHealthcareÂ® 2. Reauthorization a. Afinitor will be approved based on the following criterion: (1) Patient does not show evidence of progressive disease while on Afinitor therapy Authorization will be issued for 12 months. R. NCCN Recommended Regimens The drug has been recognized for treatment of the cancer indication by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category of Evidence and Consensus of 1, 2A, or 2B Authorization will be issued for 12 months. a State mandates may apply. Any federal regulatory requirements and the member specific benefit plan coverage may also impact coverage criteria. Other policies and utilization management programs may apply. 3. Additional Clinical Rules: Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic. Use of automated approval and re-approval processes varies by pr...\n",
      "ðŸ’¡ Caption: UnitedHealthcareÂ® 2.<em> Reauthorization a.</em>  ...) Patient <em> show evidence of progressive disease </em>while on<em> Afinitor therapy AuthorizationN</em>CCN<em> Recommended Regimens </em>The<em> drug has been recognized for treatment of the cancer indication </em>by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category of Evidence and Consensus.\n",
      "========================================\n",
      "\n",
      "========================================\n",
      "ðŸ†” ID: 677854350e06_aHR0cHM6Ly9zdG9yYWdlYWVhc3R1c2ZhY3RvcnkuYmxvYi5jb3JlLndpbmRvd3MubmV0L3ByZS1hdXRoLXBvbGljaWVzL3BvbGljaWVzX29jci8wMDUucGRm0_normalized_images_7_pages_0\n",
      "ðŸ“‚ Source Doc Path: https://storageaeastusfactory.blob.core.windows.net/pre-auth-policies/policies_ocr/005.pdf\n",
      "ðŸ“œ Content: UnitedHealthcareÂ® (2) One of the following: (a) Unresectable locoreginal recurrent disease (b) Persistent disease (c) Metastatic disease -AND- (3) One of the following: (a) Patient has symptomatic disease (b) Patient has progressive disease -AND- (4) Disease is refractory to radioactive iodine treatment Authorization will be issued for 12 months. 2. Reauthorization a. Afinitor will be approved based on the following criterion: (1) Patient does not show evidence of progressive disease while on Afinitor therapy Authorization will be issued for 12 months. L. Meningioma 1. Initial Authorization a. Afinitor will be approved based on all of the following criteria: (1) Diagnosis of meningioma -AND- (2) Disease is recurrent or progressive -AND- (3) Surgery and/or radiation is not possible -AND- (4) One of the following: (a) Used in combination with bevacizumab (Avastin, Mvasi, etc.) (b) Used in combination with octreotide acetate LAR C 2024 UnitedHealthcare Services, Inc. 8\n",
      "ðŸ’¡ Caption: UnitedHealthcareÂ® (2) One of the following: (a) Unresectable locoreginal recurrent disease (b) Persistent disease (c) Metastatic disease -AND- (3) One of the following: (a) Patient has symptomatic disease (b) Patient has progressive disease -AND- (4) Disease is refractory to<em> radioactive iodine </em>treatment Authorization will be issued for 12 months..\n",
      "========================================\n",
      "\n",
      "========================================\n",
      "ðŸ†” ID: 677854350e06_aHR0cHM6Ly9zdG9yYWdlYWVhc3R1c2ZhY3RvcnkuYmxvYi5jb3JlLndpbmRvd3MubmV0L3ByZS1hdXRoLXBvbGljaWVzL3BvbGljaWVzX29jci8wMDUucGRm0_normalized_images_9_pages_0\n",
      "ðŸ“‚ Source Doc Path: https://storageaeastusfactory.blob.core.windows.net/pre-auth-policies/policies_ocr/005.pdf\n",
      "ðŸ“œ Content: UnitedHealthcareÂ® (1) Patient does not show evidence of progressive disease while on Afinitor therapy Authorization will be issued for 12 months. O. Bone Cancer - Osteosarcoma 1. Initial Authorization a. Afinitor will be approved based on all of the following criteria: (1) Diagnosis of osteosarcoma -AND- (2) Disease is one of the following: (a) Relapsed/Refractory (b) Metastatic -AND- (3) Used as second-line therapy -AND- (4) Used in combination with Nexavar (sorafenib) Authorization will be issued for 12 months. 2. Reauthorization a. Afinitor will be approved based on the following criterion: (1) Patient does not show evidence of progressive disease while on Afinitor therapy Authorization will be issued for 12 months. P. Histiocytic Neoplasms 1. Initial Authorization a. Afinitor will be approved based on both of the following criteria: (1) Diagnosis of one of the following: (a) Rosai-Dorfman Disease (b) Langerhans Cell Histiocytosis (c) Erdheim-Chester Disease -AND- @ 2024 UnitedHealt...\n",
      "ðŸ’¡ Caption: UnitedHealthcareÂ® (1) Patient<em> does not show evidence of progressive disease </em>while on<em> Afinitor therapy Authorization </em>will be issued for 12 months. <em>Afinitor will be approved </em>based<em> on </em>all of the following criteria: (1)<em> Diagnosis of osteosarcoma -AND- </em>(2) Disease is one of the following: (a) Relapsed/Refractory (b) Metastatic -AND- (3) Used as.\n",
      "========================================\n",
      "\n",
      "========================================\n",
      "ðŸ†” ID: 677854350e06_aHR0cHM6Ly9zdG9yYWdlYWVhc3R1c2ZhY3RvcnkuYmxvYi5jb3JlLndpbmRvd3MubmV0L3ByZS1hdXRoLXBvbGljaWVzL3BvbGljaWVzX29jci8wMDUucGRm0_normalized_images_1_pages_0\n",
      "ðŸ“‚ Source Doc Path: https://storageaeastusfactory.blob.core.windows.net/pre-auth-policies/policies_ocr/005.pdf\n",
      "ðŸ“œ Content: UnitedHealthcareÂ® 2. Coverage CriteriaÂª: A. Patients less than 19 years of age 1. Afinitor will be approved based on the following criterion: a. Patient is less than 19 years of age Authorization will be issued for 12 months. B. Neuroendocrine Tumors 1. Initial Authorization a. Afinitor will be approved based on One of the following criteria: (1) All of the following: (a) Diagnosis of one of the following: (i) Neuroendocrine tumors of gastrointestinal origin (ii) Neuroendocrine tumors of lung origin (iii) Neuroendocrine tumors of thymic origin -AND- (b) Disease is progressive -AND- (c) One of the following: (i) Disease is unresectable (ii) Disease is locally advanced (iii) Disease is metastatic -OR- (2) Both of the following: (a) Diagnosis of neuroendocrine tumors of pancreatic origin -AND- (b) One of the following: (i) Used for the management of recurrent, locoregional advanced disease and/or metastatic disease (ii) Used as preoperative therapy of locoregional insulinoma with or witho...\n",
      "ðŸ’¡ Caption: UnitedHealthcareÂ® 2. <em>Coverage CriteriaÂª: </em>A.<em> Patients less than 19 years of age </em>1.  ... (1) All of the follow<em> Diagnosis of </em>one of the following: (i) Neuroendocrine tumors of gastrointestinal origin (ii) Neuroendocrine tumors of lung origin (iii) Neuroendocrine tumors of thymic origin -AND- (b) Disease is progressive -AND- (c) One of the following:.\n",
      "========================================\n",
      "\n",
      "========================================\n",
      "ðŸ†” ID: 677854350e06_aHR0cHM6Ly9zdG9yYWdlYWVhc3R1c2ZhY3RvcnkuYmxvYi5jb3JlLndpbmRvd3MubmV0L3ByZS1hdXRoLXBvbGljaWVzL3BvbGljaWVzX29jci8wMDUucGRm0_normalized_images_3_pages_0\n",
      "ðŸ“‚ Source Doc Path: https://storageaeastusfactory.blob.core.windows.net/pre-auth-policies/policies_ocr/005.pdf\n",
      "ðŸ“œ Content: UnitedHealthcareÂ® (1) Patient does not show evidence of progressive disease while on Afinitor therapy Authorization will be issued for 12 months. E. Subependymal Giant Cell Astrocytoma 1. Initial Authorization a. Afinitor will be approved based on both of the following criteria: (1) Diagnosis of subependymal giant cell astrocytoma (SEGA) -AND- (2) Used as adjuvant treatment Authorization will be issued for 12 months. 2. Reauthorization a. Afinitor will be approved based on the following criterion: (1) Patient does not show evidence of progressive disease while on Afinitor therapy Authorization will be issued for 12 months. F. WaldenstrÃ¶ms Macroglobulinemia or Lymphoplasmacytic Lymphoma 1. Initial Authorization a. Afinitor will be approved based on both the following criteria: (1) Diagnosis of one of the following: (a) WaldenstrÃ¶ms macroglobulinemia (b) Lymphoplasmacytic lymphoma -AND- (2) One of the following: (a) Disease is non-responsive to primary treatment (b) Disease is progressiv...\n",
      "ðŸ’¡ Caption: UnitedHealthcareÂ® (1)<em> Patient does not show evidence of progressive disease </em>while on<em> Afinitor therapy Authorization </em>will be<em> issued </em>for 12 months. <em>Afinitor will be approved </em>based on both of the following<em> criteria: </em>(1)<em> Diagnosis of subependymal giant cell astrocytoma (SEGA) -AND- </em>(2) Used as adjuvant treatment Authorization will be issued for 12.\n",
      "========================================\n",
      "\n",
      "========================================\n",
      "ðŸ†” ID: 677854350e06_aHR0cHM6Ly9zdG9yYWdlYWVhc3R1c2ZhY3RvcnkuYmxvYi5jb3JlLndpbmRvd3MubmV0L3ByZS1hdXRoLXBvbGljaWVzL3BvbGljaWVzX29jci8wMDUucGRm0_normalized_images_10_pages_0\n",
      "ðŸ“‚ Source Doc Path: https://storageaeastusfactory.blob.core.windows.net/pre-auth-policies/policies_ocr/005.pdf\n",
      "ðŸ“œ Content: UnitedHealthcareÂ® (2) Presence of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutation Authorization will be issued for 12 months. 2. Reauthorization a. Afinitor will be approved based on the following criterion: (1) Patient does not show evidence of progressive disease while on Afinitor therapy Authorization will be issued for 12 months. Q. Gastrointestingal Stromal Tumor (GIST) 1. Initial Authorization a. Afinitor will be approved based on all of the following criteria: (1) Diagnosis of Gastrointestinal Stromal Tumor (GIST) -AND- (2) Disease is one of the following: (a) Unresectable (b) Progressive (c) Metastatic (d) Gross residual (R2 resection) (e) Tumor rupture -AND- (3) Disease has progressed after single agent therapy with all of the following: (a) Imatinib (Gleevec) (b) Sutent (sunitinib) (c) Stivarga (regorafenib) (d) Qinlock (ripretinib) -AND- (4) Used in combination with one of the following: (a) Imatinib (Gleevec) (b) Sutent (sunitinib) (...\n",
      "ðŸ’¡ Caption: UnitedHealthcareÂ® (2) Presence of<em> phosphatidylinositol-4,5-bisphosphate </em>3-kinase catalytic subunit<em> alpha </em>(PIK3CA)<em> mutation Authorization </em>will be issued for 12 months. <em>Afinitor will be approved </em>based on all of the following criteria: (1)<em> Diagnosis of Gastrointestinal Stromal Tumor </em>(GIST) -AND- (2) Disease is one of the following: (a) Unresectable.\n",
      "========================================\n",
      "\n",
      "========================================\n",
      "ðŸ†” ID: 677854350e06_aHR0cHM6Ly9zdG9yYWdlYWVhc3R1c2ZhY3RvcnkuYmxvYi5jb3JlLndpbmRvd3MubmV0L3ByZS1hdXRoLXBvbGljaWVzL3BvbGljaWVzX29jci8wMDUucGRm0_normalized_images_2_pages_0\n",
      "ðŸ“‚ Source Doc Path: https://storageaeastusfactory.blob.core.windows.net/pre-auth-policies/policies_ocr/005.pdf\n",
      "ðŸ“œ Content: UnitedHealthcareÂ® Authorization will be issued for 12 months. 2. Reauthorization a. Afinitor will be approved based on the following criterion: (1) Patient does not show evidence of progressive disease while on Afinitor therapy Authorization will be issued for 12 months. C. Advanced Renal Cell Carcinoma/Kidney Cancer 1. Initial Authorization a. Afinitor will be approved based on both of the following criteria: (1) Diagnosis of advanced renal cell cancer/kidney cancer -AND- (2) Disease is one of the following: (a) Relapsed (b) Stage IV disease Authorization will be issued for 12 months. 2. Reauthorization a. Afinitor will be approved based on the following criterion: (1) Patient does not show evidence of progressive disease while on Afinitor therapy Authorization will be issued for 12 months. D. Tuberous Sclerosis Complex-Associated Renal Cell Carcinoma 1. Initial Authorization a. Afinitor will be approved based on the following criterion: (1) Diagnosis of tuberous sclerosis complex (TS...\n",
      "ðŸ’¡ Caption: <em>UnitedHealthcareÂ® Authorization will be issued for 12 months.</em> <em>Afinitor </em>will be<em> approved </em>based on the following criterion: (1) Patient<em> does not show evidence of progressive disease </em>while on<em> Afinitor therapy Authorization </em>will be issued for 12 months.  ...ng crite<em> Diagnosis of advanced renal cell cancer/kidney cancer </em>-AND- (2) Disease is one of the.\n",
      "======================================== (aisearch.py:semantic_search:173)\n",
      "[2024-12-18 18:22:24 - AgenticRAG - Plugin AzureSearchPlugin:173 - INFO] Extracted results: ========================================\n",
      "ðŸ†” ID: 677854350e06_aHR0cHM6Ly9zdG9yYWdlYWVhc3R1c2ZhY3RvcnkuYmxvYi5jb3JlLndpbmRvd3MubmV0L3ByZS1hdXRoLXBvbGljaWVzL3BvbGljaWVzX29jci8wMDEucGRm0_normalized_images_7_pages_1\n",
      "ðŸ“‚ Source Doc Path: https://storageaeastusfactory.blob.core.windows.net/pre-auth-policies/policies_ocr/001.pdf\n",
      "ðŸ“œ Content: Grace Index, Leeds Enthesitis Score (LEI), Spondyloarthritis Consortium of Canada (SPARCC) enthesitis score, Leeds Dactylitis Instrument Score, Minimal Disease Activity (MDA), Psoriatic Arthritis Impact of Disease (PsAID- 12), and/or serum markers (e.g ., C-reactive protein, erythrocyte sedimentation rate). b) Compared with baseline (prior to initiating an adalimumab product), patient experienced an improvement in at least one symptom, such as less joint pain, morning stiffness, or fatigue; improved function or activities of daily living; or decreased soft tissue swelling in joints or tendon sheaths. 3 Pages - Cigna National Formulary Coverage - Policy:Inflammatory Conditions - Adalimumab Products Prior Authorization Policy\n",
      "ðŸ’¡ Caption: Grace Index, Leeds Enthesitis Score (LEI), Spondyloarthritis Consortium of Canada (SPARCC) enthesitis score, Leeds Dactylitis Instrument Score, Minimal Disease Activity (MDA),<em> Psoriatic Arthritis Impact of Disease </em>(PsAID- 12), and/or serum markers (e.g ., C-reactive protein, erythrocyte sedimentation rate). b) Compared with baseline (prior to.\n",
      "========================================\n",
      "\n",
      "========================================\n",
      "ðŸ†” ID: 677854350e06_aHR0cHM6Ly9zdG9yYWdlYWVhc3R1c2ZhY3RvcnkuYmxvYi5jb3JlLndpbmRvd3MubmV0L3ByZS1hdXRoLXBvbGljaWVzL3BvbGljaWVzX29jci8wMDUucGRm0_normalized_images_5_pages_0\n",
      "ðŸ“‚ Source Doc Path: https://storageaeastusfactory.blob.core.windows.net/pre-auth-policies/policies_ocr/005.pdf\n",
      "ðŸ“œ Content: UnitedHealthcareÂ® (a) Exemestane if progressed within 12 months or on a non-steroidal aromatase inhibitor [e.g ., Arimidex (anastrozole), Femara (letrozole)] (b) Fulvestrant (c) Tamoxifen Authorization will be issued for 12 months. 2. Reauthorization a. Afinitor will be approved based on the following criterion: (1) Patient does not show evidence of progressive disease while on Afinitor therapy Authorization will be issued for 12 months. H. Hodgkin Lymphoma 1. Initial Authorization a. Afinitor will be approved based on both of the following criteria: (1) Diagnosis of classic Hodgkin lymphoma -AND- (2) Disease is refractory to at least 3 prior lines of therapy Authorization will be issued for 12 months. 2. Reauthorization a. Afinitor will be approved based on the following criterion: (1) Patient does not show evidence of progressive disease while on Afinitor therapy Authorization will be issued for 12 months. I. Soft Tissue Sarcoma 1. Initial Authorization a. Afinitor will be approved b...\n",
      "ðŸ’¡ Caption: UnitedHealthcareÂ® (a)<em> Exemestane </em>if progressed within 12 months or on a<em> non-steroidal aromatase inhibitor </em>[e.g ., Arimidex (anastrozole), Femara (letrozole)] (b) Fulvestrant (c) Tamoxifen Authorization will be issued for 12 months.  ...<em> Afinitor therapy AuthorizationH</em>.<em> Hodgkin Lymphoma </em>1. <em>Afinitor </em>will be<em> approved </em>based on both of the following.\n",
      "========================================\n",
      "\n",
      "========================================\n",
      "ðŸ†” ID: 677854350e06_aHR0cHM6Ly9zdG9yYWdlYWVhc3R1c2ZhY3RvcnkuYmxvYi5jb3JlLndpbmRvd3MubmV0L3ByZS1hdXRoLXBvbGljaWVzL3BvbGljaWVzX29jci8wMDUucGRm0_normalized_images_4_pages_0\n",
      "ðŸ“‚ Source Doc Path: https://storageaeastusfactory.blob.core.windows.net/pre-auth-policies/policies_ocr/005.pdf\n",
      "ðŸ“œ Content: UnitedHealthcareÂ® (1) Patient does not show evidence of progressive disease while on Afinitor therapy Authorization will be issued for 12 months. G. Breast Cancer 1. Initial Authorization a. Afinitor will be approved based on all of the following criteria: (1) Diagnosis of breast cancer -AND- (2) One of the following: (a) Disease is recurrent (b) Disease is metastatic -AND- (3) Disease is hormone receptor (HR)-positive [i.e ., estrogen-receptor-positive (ER+) or progesterone-receptor-positive (PR+)] -AND- (4) Disease is human epidermal growth factor receptor 2 (HER2)-negative -AND- (5) One of the following: (a) Patient is a postmenopausal woman -OR- (b) Both of the following: i. Patient is a premenopausal woman ii. Patient is being treated with ovarian ablation/suppression -OR- (c) Patient is male -AND- (6) Used in combination with one of the following: C 2024 UnitedHealthcare Services, Inc. 5\n",
      "ðŸ’¡ Caption: UnitedHealthcareÂ® (1)<em> Patient does not show evidence of progressive disease </em>while on<em> Afinitor therapy Authorization </em>will be issued for 12 months. <em>Afinitor will be approved based on </em>all of the following criteria: (1)<em> Diagnosis of breast cancer </em>-AND- (2) One of the following: (a) Disease is recurrent (b) Disease is metasta... Patient is being.\n",
      "========================================\n",
      "\n",
      "========================================\n",
      "ðŸ†” ID: 677854350e06_aHR0cHM6Ly9zdG9yYWdlYWVhc3R1c2ZhY3RvcnkuYmxvYi5jb3JlLndpbmRvd3MubmV0L3ByZS1hdXRoLXBvbGljaWVzL3BvbGljaWVzX29jci8wMDUucGRm0_normalized_images_11_pages_0\n",
      "ðŸ“‚ Source Doc Path: https://storageaeastusfactory.blob.core.windows.net/pre-auth-policies/policies_ocr/005.pdf\n",
      "ðŸ“œ Content: UnitedHealthcareÂ® 2. Reauthorization a. Afinitor will be approved based on the following criterion: (1) Patient does not show evidence of progressive disease while on Afinitor therapy Authorization will be issued for 12 months. R. NCCN Recommended Regimens The drug has been recognized for treatment of the cancer indication by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category of Evidence and Consensus of 1, 2A, or 2B Authorization will be issued for 12 months. a State mandates may apply. Any federal regulatory requirements and the member specific benefit plan coverage may also impact coverage criteria. Other policies and utilization management programs may apply. 3. Additional Clinical Rules: Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic. Use of automated approval and re-approval processes varies by pr...\n",
      "ðŸ’¡ Caption: UnitedHealthcareÂ® 2.<em> Reauthorization a.</em>  ...) Patient <em> show evidence of progressive disease </em>while on<em> Afinitor therapy AuthorizationN</em>CCN<em> Recommended Regimens </em>The<em> drug has been recognized for treatment of the cancer indication </em>by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category of Evidence and Consensus.\n",
      "========================================\n",
      "\n",
      "========================================\n",
      "ðŸ†” ID: 677854350e06_aHR0cHM6Ly9zdG9yYWdlYWVhc3R1c2ZhY3RvcnkuYmxvYi5jb3JlLndpbmRvd3MubmV0L3ByZS1hdXRoLXBvbGljaWVzL3BvbGljaWVzX29jci8wMDUucGRm0_normalized_images_7_pages_0\n",
      "ðŸ“‚ Source Doc Path: https://storageaeastusfactory.blob.core.windows.net/pre-auth-policies/policies_ocr/005.pdf\n",
      "ðŸ“œ Content: UnitedHealthcareÂ® (2) One of the following: (a) Unresectable locoreginal recurrent disease (b) Persistent disease (c) Metastatic disease -AND- (3) One of the following: (a) Patient has symptomatic disease (b) Patient has progressive disease -AND- (4) Disease is refractory to radioactive iodine treatment Authorization will be issued for 12 months. 2. Reauthorization a. Afinitor will be approved based on the following criterion: (1) Patient does not show evidence of progressive disease while on Afinitor therapy Authorization will be issued for 12 months. L. Meningioma 1. Initial Authorization a. Afinitor will be approved based on all of the following criteria: (1) Diagnosis of meningioma -AND- (2) Disease is recurrent or progressive -AND- (3) Surgery and/or radiation is not possible -AND- (4) One of the following: (a) Used in combination with bevacizumab (Avastin, Mvasi, etc.) (b) Used in combination with octreotide acetate LAR C 2024 UnitedHealthcare Services, Inc. 8\n",
      "ðŸ’¡ Caption: UnitedHealthcareÂ® (2) One of the following: (a) Unresectable locoreginal recurrent disease (b) Persistent disease (c) Metastatic disease -AND- (3) One of the following: (a) Patient has symptomatic disease (b) Patient has progressive disease -AND- (4) Disease is refractory to<em> radioactive iodine </em>treatment Authorization will be issued for 12 months..\n",
      "========================================\n",
      "\n",
      "========================================\n",
      "ðŸ†” ID: 677854350e06_aHR0cHM6Ly9zdG9yYWdlYWVhc3R1c2ZhY3RvcnkuYmxvYi5jb3JlLndpbmRvd3MubmV0L3ByZS1hdXRoLXBvbGljaWVzL3BvbGljaWVzX29jci8wMDUucGRm0_normalized_images_9_pages_0\n",
      "ðŸ“‚ Source Doc Path: https://storageaeastusfactory.blob.core.windows.net/pre-auth-policies/policies_ocr/005.pdf\n",
      "ðŸ“œ Content: UnitedHealthcareÂ® (1) Patient does not show evidence of progressive disease while on Afinitor therapy Authorization will be issued for 12 months. O. Bone Cancer - Osteosarcoma 1. Initial Authorization a. Afinitor will be approved based on all of the following criteria: (1) Diagnosis of osteosarcoma -AND- (2) Disease is one of the following: (a) Relapsed/Refractory (b) Metastatic -AND- (3) Used as second-line therapy -AND- (4) Used in combination with Nexavar (sorafenib) Authorization will be issued for 12 months. 2. Reauthorization a. Afinitor will be approved based on the following criterion: (1) Patient does not show evidence of progressive disease while on Afinitor therapy Authorization will be issued for 12 months. P. Histiocytic Neoplasms 1. Initial Authorization a. Afinitor will be approved based on both of the following criteria: (1) Diagnosis of one of the following: (a) Rosai-Dorfman Disease (b) Langerhans Cell Histiocytosis (c) Erdheim-Chester Disease -AND- @ 2024 UnitedHealt...\n",
      "ðŸ’¡ Caption: UnitedHealthcareÂ® (1) Patient<em> does not show evidence of progressive disease </em>while on<em> Afinitor therapy Authorization </em>will be issued for 12 months. <em>Afinitor will be approved </em>based<em> on </em>all of the following criteria: (1)<em> Diagnosis of osteosarcoma -AND- </em>(2) Disease is one of the following: (a) Relapsed/Refractory (b) Metastatic -AND- (3) Used as.\n",
      "========================================\n",
      "\n",
      "========================================\n",
      "ðŸ†” ID: 677854350e06_aHR0cHM6Ly9zdG9yYWdlYWVhc3R1c2ZhY3RvcnkuYmxvYi5jb3JlLndpbmRvd3MubmV0L3ByZS1hdXRoLXBvbGljaWVzL3BvbGljaWVzX29jci8wMDUucGRm0_normalized_images_1_pages_0\n",
      "ðŸ“‚ Source Doc Path: https://storageaeastusfactory.blob.core.windows.net/pre-auth-policies/policies_ocr/005.pdf\n",
      "ðŸ“œ Content: UnitedHealthcareÂ® 2. Coverage CriteriaÂª: A. Patients less than 19 years of age 1. Afinitor will be approved based on the following criterion: a. Patient is less than 19 years of age Authorization will be issued for 12 months. B. Neuroendocrine Tumors 1. Initial Authorization a. Afinitor will be approved based on One of the following criteria: (1) All of the following: (a) Diagnosis of one of the following: (i) Neuroendocrine tumors of gastrointestinal origin (ii) Neuroendocrine tumors of lung origin (iii) Neuroendocrine tumors of thymic origin -AND- (b) Disease is progressive -AND- (c) One of the following: (i) Disease is unresectable (ii) Disease is locally advanced (iii) Disease is metastatic -OR- (2) Both of the following: (a) Diagnosis of neuroendocrine tumors of pancreatic origin -AND- (b) One of the following: (i) Used for the management of recurrent, locoregional advanced disease and/or metastatic disease (ii) Used as preoperative therapy of locoregional insulinoma with or witho...\n",
      "ðŸ’¡ Caption: UnitedHealthcareÂ® 2. <em>Coverage CriteriaÂª: </em>A.<em> Patients less than 19 years of age </em>1.  ... (1) All of the follow<em> Diagnosis of </em>one of the following: (i) Neuroendocrine tumors of gastrointestinal origin (ii) Neuroendocrine tumors of lung origin (iii) Neuroendocrine tumors of thymic origin -AND- (b) Disease is progressive -AND- (c) One of the following:.\n",
      "========================================\n",
      "\n",
      "========================================\n",
      "ðŸ†” ID: 677854350e06_aHR0cHM6Ly9zdG9yYWdlYWVhc3R1c2ZhY3RvcnkuYmxvYi5jb3JlLndpbmRvd3MubmV0L3ByZS1hdXRoLXBvbGljaWVzL3BvbGljaWVzX29jci8wMDUucGRm0_normalized_images_3_pages_0\n",
      "ðŸ“‚ Source Doc Path: https://storageaeastusfactory.blob.core.windows.net/pre-auth-policies/policies_ocr/005.pdf\n",
      "ðŸ“œ Content: UnitedHealthcareÂ® (1) Patient does not show evidence of progressive disease while on Afinitor therapy Authorization will be issued for 12 months. E. Subependymal Giant Cell Astrocytoma 1. Initial Authorization a. Afinitor will be approved based on both of the following criteria: (1) Diagnosis of subependymal giant cell astrocytoma (SEGA) -AND- (2) Used as adjuvant treatment Authorization will be issued for 12 months. 2. Reauthorization a. Afinitor will be approved based on the following criterion: (1) Patient does not show evidence of progressive disease while on Afinitor therapy Authorization will be issued for 12 months. F. WaldenstrÃ¶ms Macroglobulinemia or Lymphoplasmacytic Lymphoma 1. Initial Authorization a. Afinitor will be approved based on both the following criteria: (1) Diagnosis of one of the following: (a) WaldenstrÃ¶ms macroglobulinemia (b) Lymphoplasmacytic lymphoma -AND- (2) One of the following: (a) Disease is non-responsive to primary treatment (b) Disease is progressiv...\n",
      "ðŸ’¡ Caption: UnitedHealthcareÂ® (1)<em> Patient does not show evidence of progressive disease </em>while on<em> Afinitor therapy Authorization </em>will be<em> issued </em>for 12 months. <em>Afinitor will be approved </em>based on both of the following<em> criteria: </em>(1)<em> Diagnosis of subependymal giant cell astrocytoma (SEGA) -AND- </em>(2) Used as adjuvant treatment Authorization will be issued for 12.\n",
      "========================================\n",
      "\n",
      "========================================\n",
      "ðŸ†” ID: 677854350e06_aHR0cHM6Ly9zdG9yYWdlYWVhc3R1c2ZhY3RvcnkuYmxvYi5jb3JlLndpbmRvd3MubmV0L3ByZS1hdXRoLXBvbGljaWVzL3BvbGljaWVzX29jci8wMDUucGRm0_normalized_images_10_pages_0\n",
      "ðŸ“‚ Source Doc Path: https://storageaeastusfactory.blob.core.windows.net/pre-auth-policies/policies_ocr/005.pdf\n",
      "ðŸ“œ Content: UnitedHealthcareÂ® (2) Presence of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutation Authorization will be issued for 12 months. 2. Reauthorization a. Afinitor will be approved based on the following criterion: (1) Patient does not show evidence of progressive disease while on Afinitor therapy Authorization will be issued for 12 months. Q. Gastrointestingal Stromal Tumor (GIST) 1. Initial Authorization a. Afinitor will be approved based on all of the following criteria: (1) Diagnosis of Gastrointestinal Stromal Tumor (GIST) -AND- (2) Disease is one of the following: (a) Unresectable (b) Progressive (c) Metastatic (d) Gross residual (R2 resection) (e) Tumor rupture -AND- (3) Disease has progressed after single agent therapy with all of the following: (a) Imatinib (Gleevec) (b) Sutent (sunitinib) (c) Stivarga (regorafenib) (d) Qinlock (ripretinib) -AND- (4) Used in combination with one of the following: (a) Imatinib (Gleevec) (b) Sutent (sunitinib) (...\n",
      "ðŸ’¡ Caption: UnitedHealthcareÂ® (2) Presence of<em> phosphatidylinositol-4,5-bisphosphate </em>3-kinase catalytic subunit<em> alpha </em>(PIK3CA)<em> mutation Authorization </em>will be issued for 12 months. <em>Afinitor will be approved </em>based on all of the following criteria: (1)<em> Diagnosis of Gastrointestinal Stromal Tumor </em>(GIST) -AND- (2) Disease is one of the following: (a) Unresectable.\n",
      "========================================\n",
      "\n",
      "========================================\n",
      "ðŸ†” ID: 677854350e06_aHR0cHM6Ly9zdG9yYWdlYWVhc3R1c2ZhY3RvcnkuYmxvYi5jb3JlLndpbmRvd3MubmV0L3ByZS1hdXRoLXBvbGljaWVzL3BvbGljaWVzX29jci8wMDUucGRm0_normalized_images_2_pages_0\n",
      "ðŸ“‚ Source Doc Path: https://storageaeastusfactory.blob.core.windows.net/pre-auth-policies/policies_ocr/005.pdf\n",
      "ðŸ“œ Content: UnitedHealthcareÂ® Authorization will be issued for 12 months. 2. Reauthorization a. Afinitor will be approved based on the following criterion: (1) Patient does not show evidence of progressive disease while on Afinitor therapy Authorization will be issued for 12 months. C. Advanced Renal Cell Carcinoma/Kidney Cancer 1. Initial Authorization a. Afinitor will be approved based on both of the following criteria: (1) Diagnosis of advanced renal cell cancer/kidney cancer -AND- (2) Disease is one of the following: (a) Relapsed (b) Stage IV disease Authorization will be issued for 12 months. 2. Reauthorization a. Afinitor will be approved based on the following criterion: (1) Patient does not show evidence of progressive disease while on Afinitor therapy Authorization will be issued for 12 months. D. Tuberous Sclerosis Complex-Associated Renal Cell Carcinoma 1. Initial Authorization a. Afinitor will be approved based on the following criterion: (1) Diagnosis of tuberous sclerosis complex (TS...\n",
      "ðŸ’¡ Caption: <em>UnitedHealthcareÂ® Authorization will be issued for 12 months.</em> <em>Afinitor </em>will be<em> approved </em>based on the following criterion: (1) Patient<em> does not show evidence of progressive disease </em>while on<em> Afinitor therapy Authorization </em>will be issued for 12 months.  ...ng crite<em> Diagnosis of advanced renal cell cancer/kidney cancer </em>-AND- (2) Disease is one of the.\n",
      "========================================\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "AI Response: ### The Impact of AI on Medical Diagnostics\n",
      "\n",
      "Artificial Intelligence (AI) is revolutionizing various industries, with healthcare being a prominent field witnessing significant advancements. The application of AI in medical diagnostics holds transformative potential, enhancing the precision, efficiency, and accessibility of diagnostic services. This document explores the detailed insights, key findings, and relevant research supporting the impact of AI on medical diagnostics, along with clinical evaluations and expert reviews to ensure comprehensive and accurate content.\n",
      "\n",
      "#### Introduction to AI in Medical Diagnostics\n",
      "AI leverages machine learning algorithms, natural language processing, and advanced data analytics to assist healthcare professionals in diagnosing diseases. These technologies can analyze complex medical data, recognize patterns, and provide accurate predictions, thereby augmenting the diagnostic process.\n",
      "\n",
      "#### Key Findings and Insights\n",
      "\n",
      "1. **Enhanced Diagnostic Accuracy**:\n",
      "   - AI algorithms can analyze vast datasets from imaging modalities (e.g., MRI, CT scans, X-rays) with higher accuracy and speed compared to human radiologists. Studies have shown that AI can match or surpass human performance in identifying certain conditions, such as diabetic retinopathy and lung cancer.\n",
      "   - For instance, a study published in *Nature* reported that an AI system developed by Google Health demonstrated a high level of accuracy in detecting breast cancer in mammograms, reducing false positives and negatives.\n",
      "\n",
      "2. **Early Detection of Diseases**:\n",
      "   - AI systems excel in early disease detection, which is crucial for conditions like cancer, where early diagnosis can significantly improve prognosis. AI's ability to detect minute anomalies in medical images can lead to earlier interventions.\n",
      "   - The application of AI in screening programs has been associated with improved detection rates for various cancers, including skin cancer and colorectal cancer.\n",
      "\n",
      "3. **Clinical Decision Support**:\n",
      "   - AI-driven decision support systems (DSS) assist clinicians by providing evidence-based recommendations for diagnosis and treatment, improving overall patient care. These systems integrate patient history, diagnostic data, and current medical guidelines to suggest optimal clinical pathways.\n",
      "   - AI-enabled DSS have been shown to reduce diagnostic errors, enhance treatment consistency, and support personalized medicine approaches.\n",
      "\n",
      "4. **Operational Efficiency**:\n",
      "   - AI streamlines diagnostic workflows by automating routine tasks, such as image sorting, segmentation, and preliminary analysis, allowing healthcare professionals to focus on more complex and critical aspects of patient care.\n",
      "   - Hospitals and diagnostic centers adopting AI have reported reduced turnaround times for diagnostic results and improved patient throughput.\n",
      "\n",
      "#### Relevant Research\n",
      "\n",
      "1. **AI in Radiology**:\n",
      "   - A comprehensive review in the *Journal of the American College of Radiology* highlighted the significant role of AI in radiology, emphasizing its effectiveness in image recognition, anomaly detection, and workflow optimization.\n",
      "   - Research from Stanford University demonstrated that AI algorithms could diagnose pneumonia from chest X-rays with similar accuracy to radiologists, showcasing the potential for AI to support overburdened radiology departments.\n",
      "\n",
      "2. **AI in Pathology**:\n",
      "   - PathAI, an AI-powered pathology platform, has shown promising results in analyzing histopathological images to diagnose diseases like cancer. Studies have indicated that AI can improve diagnostic accuracy in pathology, assisting pathologists in identifying malignant cells more effectively.\n",
      "   - An article in *The Lancet Oncology* detailed the success of AI in diagnosing prostate cancer from biopsy samples, reducing inter-pathologist variability and enhancing diagnostic reliability.\n",
      "\n",
      "#### Clinical Evaluations and Expert Reviews\n",
      "\n",
      "1. **Clinical Trials and Evaluations**:\n",
      "   - Numerous clinical trials are underway to evaluate the efficacy and safety of AI in diagnostics. For example, a trial conducted by the Mayo Clinic is investigating the use of AI in diagnosing cardiovascular diseases through echocardiograms.\n",
      "   - Clinical evaluations of AI tools have consistently shown that when AI is used as an adjunct to human expertise, diagnostic accuracy improves, leading to better patient outcomes.\n",
      "\n",
      "2. **Expert Opinions**:\n",
      "   - Leading experts in the field, such as Dr. Eric Topol, have advocated for the integration of AI in healthcare. In his book, \"Deep Medicine: How Artificial Intelligence Can Make Healthcare Human Again,\" Dr. Topol discusses how AI can restore the human touch in medicine by reducing the administrative burden on clinicians, allowing them to spend more time with patients.\n",
      "   - The American Medical Association (AMA) has also emphasized the potential of AI to enhance clinical practice, advocating for the incorporation of AI into medical education to prepare future healthcare professionals for AI-integrated practice environments.\n",
      "\n",
      "### Conclusion\n",
      "The impact of AI on medical diagnostics is profound, offering significant advancements in diagnostic accuracy, early disease detection, clinical decision support, and operational efficiency. As AI technologies continue to evolve, their integration into medical diagnostics will likely become more widespread, transforming how diseases are diagnosed and managed. Continuous research, clinical evaluations, and expert insights will be crucial in guiding the ethical and effective implementation of AI in healthcare.\n",
      "\n",
      "#### References\n",
      "1. McKinney, S. M., et al. (2020). International evaluation of an AI system for breast cancer screening. *Nature*, 577(7788), 89-94.\n",
      "2. Bien, N., Rajpurkar, P., Ball, R. L., Irvin, J., Park, A., Jones, E., ... & Ng, A. Y. (2018). Deep-learning-assisted diagnosis for knee magnetic resonance imaging: Development and retrospective validation of MRNet. *PLoS medicine*, 15(11), e1002699.\n",
      "3. Topol, E. (2019). *Deep Medicine: How Artificial Intelligence Can Make Healthcare Human Again*. Basic Books.\n",
      "4. Hosny, A., Parmar, C., Quackenbush, J., Schwartz, L. H., & Aerts, H. J. (2018). Artificial intelligence in radiology. *Nature Reviews Cancer*, 18(8), 500-510.\n",
      "\n",
      "This document provides a thorough overview of the current landscape of AI in medical diagnostics, supported by empirical research and expert evaluations.\n"
     ]
    }
   ],
   "source": [
    "from semantic_kernel.functions.kernel_arguments import KernelArguments\n",
    "from semantic_kernel.contents.chat_history import ChatHistory\n",
    "import logging\n",
    "from semantic_kernel.utils.logging import setup_logging\n",
    "\n",
    "# Create a history of the conversation\n",
    "chat_history = ChatHistory()\n",
    "\n",
    "# Add system message to the chat history to define the system's role\n",
    "chat_history.add_system_message(\n",
    "    \"You are an AI-powered assistant specializing in producing high-quality medical research papers. \"\n",
    "    \"Your goal is to assist users in creating comprehensive and accurate medical documents. \"\n",
    "    \"You should generate relevant research, evaluate clinical data, and provide thorough evaluations to support the content.\"\n",
    ")\n",
    "\n",
    "# User message containing a detailed query\n",
    "chat_history.add_user_message(\n",
    "    \"I would like to produce a high-quality medical document on the topic of 'The impact of AI on medical diagnostics.' \"\n",
    "    \"Please provide detailed insights, key findings, and relevant research to support this topic. \"\n",
    "    \"Additionally, include clinical evaluations and expert reviews to ensure the content is accurate and comprehensive.\"\n",
    ")\n",
    "\n",
    "# Set up logging\n",
    "logging.basicConfig(\n",
    "    format=\"[%(asctime)s - %(name)s:%(lineno)d - %(levelname)s] %(message)s\",\n",
    "    datefmt=\"%Y-%m-%d %H:%M:%S\",\n",
    ")\n",
    "setup_logging()\n",
    "logging.getLogger(\"kernel\").setLevel(logging.INFO)\n",
    "\n",
    "# Get the response from the AI\n",
    "result = (await chat_completion.get_chat_message_contents(\n",
    "    chat_history=chat_history,\n",
    "    settings=execution_settings,\n",
    "    kernel=kernel,\n",
    "    arguments=KernelArguments(input=\"The impact of AI on medical diagnostics\"),\n",
    "))[0]\n",
    "\n",
    "# Print the result\n",
    "print(\"AI Response:\", result)"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "pa-ai-env",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.15"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
